Dora

There is no image.

Desloratadine

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dora

Quick Facts

Property	Description
Active ingredient	Desloratadine
Form	Tablet, Syrup, Solution (Oral)
Pharmacological class	Selective H₁-receptor antagonist
Common use	Relief of allergic symptoms
Origin	Synthetic (Major active metabolite of Loratadine)

What Type of Medicine is Dora (Desloratadine)?

Dora is a medication whose active ingredient is Desloratadine, which is classified as a second-generation antihistamine. This substance belongs to the pharmacological class of selective H₁-receptor antagonists, a property clinically recognized for its precise targeting of allergy mechanisms. It is used as a systemic antihistamine. Its structural profile prevents it from significantly crossing the blood-brain barrier, which is the differentiating factor defining it as a non-sedating agent compared to older compounds. Desloratadine is considered the major active metabolite of the parent drug, Loratadine, which contributes to its direct and reliable action profile.

Composition, Origin, and Available Forms

The product contains a single active ingredient—Desloratadine—making it a monocomponent drug. As a synthetic compound, Desloratadine is the chemically produced, biologically active successor of Loratadine. The medicine is manufactured for oral administration and is generally available in several practical dosage forms, often including a flavored syrup or oral solution in addition to the standard tablet and film-coated tablet. The availability of a liquid form positions the product as suitable for a broad target audience, including both adults and the pediatric population, ensuring flexible and accurate administration.

General Purpose: How It Counteracts Allergic Triggers

The general purpose of Desloratadine is to relieve the physical discomfort and manifestations caused by the body's natural allergic response, such as seasonal discomfort or skin reactions. It achieves this by functioning as a peripheral H₁-receptor antagonist, competitively blocking the action of histamine, which is the primary chemical released by immune cells during an allergic event. This targeted, long-lasting action helps to interrupt the symptomatic cascade that typically leads to itching, swelling, and fluid accumulation, representing the medicine's fundamental utility in maintaining patient comfort.

Regulatory References

Desloratadine EPAR (Aerius)

What side effects are possible with Dora?

Official Regulatory Safety Profile

The safety profile for Dora (Desloratadine) is formally classified by regulatory authorities, grouping adverse reactions based on frequency and the body system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are documented according to the likelihood observed in clinical trials and post-marketing surveillance, consistent with international regulatory standards.

Classification	Examples of Documented Reactions
Common	Headache, dry mouth, and fatigue. These effects are often reported at the beginning of treatment.
Very Rare	Hallucinations, dizziness, insomnia, psychomotor hyperactivity, convulsions, tachycardia (fast heart rate), palpitations, abdominal pain, nausea, vomiting, dyspepsia, diarrhea, myalgia, and elevations of liver enzymes.

Serious Adverse Reactions and Safety Constraints

Official labeling explicitly documents rare but clinically significant events. Serious adverse reactions identified in regulatory surveillance include hypersensitivity reactions (such as anaphylaxis and angioedema), convulsions, and hepatitis (liver inflammation). The drug is contraindicated in patients with a known hypersensitivity to Desloratadine, to the inactive ingredients, or to its parent drug, Loratadine.

Population-Specific Safety Notes

The regulatory safety data includes specific observations for certain populations. Individuals with renal impairment or hepatic impairment may experience increased systemic exposure to Desloratadine. In pediatric patients, specific adverse events such as diarrhea and fever were noted more frequently in the youngest age groups.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents emphasize that in the event of a suspected overdosage with desloratadine (Dora), it is mandatory to seek immediate medical attention. The clinical signs of overdose documented in labeling often center on the central nervous system and cardiovascular effects.

Overdosage presentations observed in clinical studies involving doses significantly exceeding the maximum recommended dose include somnolence, general drowsiness, and an increased heart rate (tachycardia).

Required Emergency Actions

The fundamental principle for overdose management is immediate symptomatic and supportive treatment, as the regulatory profile explicitly states that no specific antidote is known for desloratadine. Procedures may be initiated to remove unabsorbed drug from the gastrointestinal tract, such as the use of activated charcoal or other appropriate methods, based on clinical judgment. Given the potential for cardiovascular effects, cardiovascular monitoring and continuous observation of vital signs are required, often necessitating hospital monitoring.

Regulatory authorities mandate that any suspected overdosage requires immediate notification of a healthcare professional and urgent medical evaluation.

Therapeutic Uses of Dora

What Dora Treats: Main Uses and Benefits

The medication is commonly used across therapeutic domains where additional symptomatic support is needed in situations involving distressing symptoms related to allergic responses. It is considered relevant in contexts involving heightened systemic burden across core therapeutic areas, primarily applied in addressing allergic rhinitis (both seasonal and perennial) and chronic idiopathic urticaria (hives).

Symptom Management and Therapeutic Support

Dora is relevant for easing symptoms that cluster into patterns requiring supportive management, such as those related to the primary upper respiratory and ocular irritation (sneezing, runny nose, nasal stuffiness, itchy/watery eyes) and cutaneous allergic manifestations (skin pruritus, wheals). This symptomatic assistance is relevant when symptoms interfere with daily comfort, and may help ease the overall symptom burden, supporting general well-being during symptomatic phases.

This supportive role is relevant in situations where symptoms may intensify temporarily, such as during seasonal flare-ups or for the discomfort of chronic hives. This medicine is commonly used to help with groups of symptoms that may appear suddenly or intensify over time.

Quick Fact: Relief for Allergic Discomfort
Primary focus	Managing symptoms related to inflammatory or irritative states.
Benefit area	Eases symptoms related to inflammatory or irritative states across nasal, ocular, and cutaneous domains.
Use context	Conditions characterized by episodic or fluctuating symptoms.

Eligibility and Restrictions for Use

Dora (daridorexant) is approved for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. Before initiating treatment, patients should discuss their full medical history with a healthcare provider to ensure the medication is appropriate for their individual needs.

Elderly patients may use Dora, as studies have not shown limitations specific to this population. However, caution is advised due to the increased risk of daytime sleepiness, drowsiness, and falls in older adults.

Contraindications and Warnings

There are specific conditions where the use of Dora is not recommended or requires careful medical supervision. Dora is contraindicated (should not be used) in patients with:

Condition	Recommendation
Narcolepsy (a sleep disorder involving excessive daytime sleepiness)	Should not be used
Known allergy to daridorexant or any ingredients in the tablet	Should not be used
Severe liver disease	Use is not recommended

Use with caution is necessary for patients with a history of depression or other mental illness, cataplexy, or breathing/lung problems such as chronic obstructive pulmonary disease (COPD) or sleep apnea. The medication's effects may be increased in patients with moderate liver disease, which may necessitate a cautious approach to dosing.

What should I know about interactions with other medicines?

The official regulatory profile for desloratadine is primarily characterized by pharmacokinetic interactions with specific medicines that affect its metabolism, leading to elevated concentrations of the drug in the bloodstream. However, a key aspect of the drug's official interaction profile is the lack of certain expected pharmacodynamic interactions.

Pharmacokinetic Interaction Data

Co-administration with substances that inhibit hepatic metabolism results in increased plasma concentrations of desloratadine and its active metabolite, 3-hydroxydesloratadine. Specific medicines shown to increase exposure include: Ketoconazole, Erythromycin, Azithromycin, Fluoxetine, and Cimetidine. Despite these documented increases in exposure ( C max and AUC), the regulatory authorities note that no clinically relevant changes in the safety profile were observed in controlled studies.

Co-administered Substance	Effect on Desloratadine Exposure
Ketoconazole	Increased C max and AUC
Erythromycin	Increased C max and AUC
Cimetidine	Increased C max and AUC

Alcohol, Food, and Timing Rules

Alcohol: Clinical pharmacology trials demonstrated that desloratadine did not potentiate the performance-impairing effects of alcohol. Nevertheless, caution is officially recommended due to post-marketing reports of alcohol intolerance or intoxication.

Food: The drug may be taken without regard to meals, as food does not affect the absorption of desloratadine. No mandatory time separation rules are specified for co-administration with other medicines or products in the regulatory label.

Population-Specific Interaction Notes

Pharmacokinetic data indicates that patients with renal impairment and hepatic impairment experience increased systemic exposure to desloratadine. This is a population-dependent consideration related to drug clearance, as noted in the official prescribing information.

Mechanism of Action

How Dora Works: Mechanistic Action

Dora's pharmacodynamic mechanism is defined by its function as a Dual Orexin Receptor Antagonist (DORA). Its action involves binding selectively to the two main orexin receptors, OX1 R and OX2 R, within the central nervous system. This molecular interaction interrupts the signaling pathway mediated by the orexin/hypocretin neuropeptides, which are key regulators of wakefulness and central arousal. The antagonism blocks the excitatory signals typically transduced by these receptors to various downstream wake-promoting nuclei in the brainstem and hypothalamus. This focused modulation of the arousal pathway alters the balance of the sleep-wake cycle by reducing the overall strength of wake-promoting signaling. The resulting physiological effect is a change in neural activity that reduces the latency to sleep and influences the stability of the sleep state.

Dosage and Administration Information

The drug Doravirine is an oral medication with a precise set of instructions for use.

The following structure outlines the procedural steps and conditions for administration.

Instruction Map: How to use Doravirine — administration guidelines

Administration scope	Detail
Route of administration	Oral (by mouth)
Dosing schedule	One 100 mg tablet once daily
Timing in relation to meals	Can be taken with or without food
Preparation requirements	None stated; tablet is taken whole
Age-group administration rules	Recommended dosage applies to adults and pediatric patients weighing at least 35 kg.
Missed-dose rules	If a dose is missed within 12 hours of the usual time, take it as soon as possible and resume the normal schedule. If a dose is missed by more than 12 hours, do not take the missed dose; instead, take the next dose at the regularly scheduled time. Do not take two doses at once.
Special procedural conditions	If co-administered with Rifabutin (or other moderate CYP3A inducers), the dosage is increased to one tablet twice daily (approximately 12 hours apart) for the duration of the co-administration.

Instruction classifications (high-level)	Detail
Administration method type	Oral
Frequency pattern	Daily (Once Daily)
Use-context constraints	Dosage adjustment is required when co-administered with certain medications, such as Rifabutin.

Resulting procedural structure Official step sequence:

Take one (100 mg) tablet by mouth.
Take the tablet once daily (every 24 hours).
The tablet may be taken with or without food.
If co-administering with Rifabutin, take one tablet twice daily (approximately 12 hours apart) for the entire duration of the Rifabutin course.

Connection to the overall use protocol (2–4 sentences): The protocol mandates a straightforward once-daily oral administration, which is permitted irrespective of meal timing, providing convenience for the user. However, adherence to the precise dosing frequency is critical, and a clear set of rules exists for handling a missed dose to prevent potential gaps in therapy. A specific procedural adjustment to a twice-daily regimen is required when the drug is used concurrently with certain interacting medications like Rifabutin to ensure adequate drug concentration is maintained.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dora

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research has primarily explored Dora's application in conditions characterized by fluctuating or episodic manifestations, such as allergic rhinitis. Studies conducted during periods of increased symptom activity include short-term Randomized Controlled Trials (RCTs) and meta-analyses that pool data from multiple trials. These studies explored how symptoms change over time. Researchers focused on measuring how symptoms evolved over defined time intervals, typically lasting from two to six weeks.

The studies monitored outcomes related to physical discomfort, specifically tracking changes in a Total Symptom Score (TSS) that measured outcomes linked to inflammatory or irritative states. Findings describe patterns observed in the studies relevant in trials assessing short-term or episodic symptom patterns. Comparative evidence is lacking for head-to-head research against every other non-drowsy medication.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Dora was also studied for its use in conditions involving periods of heightened symptoms, specifically chronic idiopathic urticaria (CIU), or chronic hives. Research describes an evidence structure that relies on placebo-controlled RCTs and systematic reviews. Studies explored short-term symptom changes, with research conducted during periods of increased symptom activity, typically over periods of four to six weeks.

The research examined symptom intensity or variability using the Urticaria Activity Score (UAS), which includes outcomes linked to inflammatory or irritative states. Studies monitored outcomes reflecting daily functioning or activity level.

Long-Term Studies, Special Populations, and Limitations

Most core clinical trials focused on short-term outcomes. Follow-up durations were limited in the core trials, meaning long-term effects and the consistency of observed patterns over many months are not fully established across the entire patient population. However, some research has explored Dora’s use in pediatric subjects, including children as young as six months.

Evidence is limited regarding certain global patient groups and the specific symptomatic patterns in those with certain coexisting medical conditions, such as older adults with comorbidity-defined groups. Research highlights that sample sizes for certain subgroups, such as the youngest pediatric patients, were modest.

Key Studies & References

How should Dora be stored and disposed of?

How to Store and Dispose of Dora (Desloratadine)

Official regulatory documents define strict storage and disposal requirements for Desloratadine to ensure product quality and public safety.

Storage Conditions

Desloratadine tablets must be stored at Controlled Room Temperature, which is 20^circC to 25^circC (68^circF to 77^circF), and should be kept away from light, heat, and moisture. The medication must remain in its original, tightly closed container.

Specific handling rules apply to the liquid form: the oral solution must not be frozen and must be discarded 2 months after first opening the bottle.

Disposal and Safety

All forms of this medicine must be kept out of the sight and reach of children.

Unused or expired product should be disposed of using an authorized drug take-back program. If a take-back option is unavailable, the product may be mixed with an undesirable substance in a sealed container and placed in household trash, following local regulations and avoiding disposal via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z